$1.67
6.98% today
NYSE, Apr 03, 06:46 pm CET
ISIN
US74168J1016
Symbol
PRME
Sector
Industry

Prime Medicine Stock price

$1.79
-0.45 19.91% 1M
-1.64 47.81% 6M
-1.13 38.70% YTD
-4.53 71.68% 1Y
-15.21 89.47% 3Y
-15.21 89.47% 5Y
-15.21 89.47% 10Y
NYSE, Closing price Wed, Apr 02 2025
+0.01 0.28%
ISIN
US74168J1016
Symbol
PRME
Sector
Industry

Key metrics

Market capitalization $234.78m
Enterprise Value $85.13m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 28.57
P/S ratio (TTM) P/S ratio 78.79
P/B ratio (TTM) P/B ratio 1.53
Revenue (TTM) Revenue $2.98m
EBIT (operating result TTM) EBIT $-202.47m
Free Cash Flow (TTM) Free Cash Flow $-130.16m
Cash position $190.44m
EPS (TTM) EPS $-1.70
P/E forward negative
P/S forward 14.22
EV/Sales forward 5.16
Short interest 28.43%
Show more

Is Prime Medicine a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Prime Medicine Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Prime Medicine forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Prime Medicine forecast:

Buy
91%
Hold
9%

Financial data from Prime Medicine

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2.98 2.98
-
100%
- Direct Costs 6.13 6.13
56% 56%
206%
-3.15 -3.15
78% 78%
-106%
- Selling and Administrative Expenses 38 38
149% 149%
1,272%
- Research and Development Expense 155 155
5% 5%
5,211%
-196 -196
11% 11%
-6,589%
- Depreciation and Amortization 6.13 6.13
56% 56%
206%
EBIT (Operating Income) EBIT -202 -202
6% 6%
-6,794%
Net Profit -196 -196
1% 1%
-6,573%

In millions USD.

Don't miss a Thing! We will send you all news about Prime Medicine directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prime Medicine Stock News

Positive
The Motley Fool
14 days ago
News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine (PRME) across recent trading sessions. According to data compiled by S&P Global Market Intelligence, in reaction, bullish investors were propelling the company's stock over 12% higher week to date as of early Thursday evening.
Positive
The Motley Fool
15 days ago
Shares of Prime Medicine (PRME 12.50%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.
Neutral
GlobeNewsWire
16 days ago
-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform; leverages proprietary, universal liver LNP --
More Prime Medicine News

Company Profile

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Head office United States
CEO Keith Gottesdiener
Employees 214
Founded 2019
Website www.primemedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today